Form 8-K - Current report:
SEC Accession No. 0001193125-26-093948
Filing Date
2026-03-05
Accepted
2026-03-05 16:10:24
Documents
12
Period of Report
2026-03-05
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K lctx-20260305.htm   iXBRL 8-K 45604
2 EX-99.1 lctx-ex99_1.htm EX-99.1 485369
3 GRAPHIC img176613450_0.jpg GRAPHIC 41153
  Complete submission text file 0001193125-26-093948.txt   717685

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT lctx-20260305.xsd EX-101.SCH 23883
14 EXTRACTED XBRL INSTANCE DOCUMENT lctx-20260305_htm.xml XML 4516
Mailing Address 2173 SALK AVENUE SUITE 200 CARLSBAD CA 92008
Business Address 2173 SALK AVENUE SUITE 200 CARLSBAD CA 92008 5105213390
Lineage Cell Therapeutics, Inc. (Filer) CIK: 0000876343 (see all company filings)

EIN.: 943127919 | State of Incorp.: CA | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-12830 | Film No.: 26726196
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)